Tergus Pharma Competitors and Similar CompaniesClear all

Tergus Pharma's competitors and similar companies include Novartis, Pfizer, Quantum Hi-Tech (China) Biological and Fortrea.

	Tergus Pharma Tergus Pharma is a company that offers pharmaceutical product development services.	Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products.	Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.	Quantum Hi-Tech (China) Biological Quantum Hi-Tech (China) Biological is a biotechnology company.	Fortrea Fortrea Holdings (formerly known as Labcorp Clinical Development and Commercialization Services) is a contract research organization (CRO).
Founding Date	Founding Date 1994	Founding Date 1996	Founding Date 1849	Founding Date 2000	Founding Date 2023
Type	Type Private	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development oncology pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma
Locations	Locations Durham, US HQ	Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more	Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more	Locations Guang Zhou Shi, CN HQ	Locations Durham, US HQ Buenos Aires, AR Melbourne, AU Sydney, AU Zaventem, BE Sao Paulo, BR Sofia, BG see more
Employees	Employees 582% decrease	Employees 75,883	Employees 81,0008% decrease	Employees 1,814	Employees 19,000
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 163.9 b	Valuation ($) N/A	Valuation ($) 1.6 b
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $56.7b (FY, 2025)	Revenue (est.) $62.6b (FY, 2025)	Revenue (est.) ¥1.1b (FY, 2025)	Revenue (est.) $2.7b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods $8.4b (FY, 2025)	Cost of goods $16.1b (FY, 2025)	Cost of goods ¥810m (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit $49.8b (FY, 2025)	Gross profit $46.5b (FY, 2025)	Gross profit ¥320.9m (FY, 2025)	Gross profit N/A
Net income	Net income N/A	Net income $14b (FY, 2025)	Net income $7.8b (FY, 2025)	Net income ¥13.6m (FY, 2025)	Net income ($986.2m) (FY, 2025)
Operating ⚠
Countries	Countries N/A	Countries N/A	Countries 200 (FY, 2024)	Countries N/A	Countries 90 (Jul, 2023)
Phase III Trials Products	Phase III Trials Products N/A	Phase III Trials Products 44 (FY, 2022)	Phase III Trials Products 32 (FY, 2024)	Phase III Trials Products N/A	Phase III Trials Products N/A
Registration Phase Products	Registration Phase Products N/A	Registration Phase Products 8 (FY, 2022)	Registration Phase Products 5 (FY, 2024)	Registration Phase Products N/A	Registration Phase Products N/A